Compare AKBA & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | RXST |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.0M | 305.0M |
| IPO Year | 2014 | 2021 |
| Metric | AKBA | RXST |
|---|---|---|
| Price | $1.43 | $7.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 10 |
| Target Price | $5.25 | ★ $9.78 |
| AVG Volume (30 Days) | ★ 2.2M | 775.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.14 | $5.90 |
| 52 Week High | $4.08 | $16.73 |
| Indicator | AKBA | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 57.03 |
| Support Level | $1.30 | $7.34 |
| Resistance Level | $1.55 | $9.11 |
| Average True Range (ATR) | 0.08 | 0.43 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 42.37 | 89.84 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.